Clinically, exogenous human EPO initiated shortly after birth, although could result in angiogenesis, was not found to increase the risk of severe ROP (Preterm Erythropoietin Neuroprotection Trial, PENUT) (236). Here, EPO is linked to retinopathy of prematurity.